Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis

Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914

Frequency Dependence of Signal Power and Spatial Reach of the Local Field Potential

Leski, S., Lindén, H., Tetzlaff, T., Pettersen, K. H., & Einevoll, G. T. (2013) · PubMed · doi:10.18154/rwth-conv-084442 · Cited by 3,639

Reactive Oxygen Species and the Central Nervous System

Halliwell, B. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10990.x · Cited by 2,947

Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations

Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149

Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system

Ungerstedt, U., & Arbuthnott, G. W. (1970) · Brain Research · doi:10.1016/0006-8993(70)90187-3 · Cited by 1,978

Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems

Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867

An Essay on the Shaking Palsy

Parkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628

Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria

Turrens, J. F., & Boveris, A. (1980) · Biochemical Journal · doi:10.1042/bj1910421 · Cited by 1,601

6-hydroxy-dopamine induced degeneration of central monoamine neurons

Ungerstedt, U. (1968) · European Journal of Pharmacology · doi:10.1016/0014-2999(68)90164-7 · Cited by 1,460

Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease

Dexter, D. T., Carter, C. J., Wells, F. R., Javoy‐Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397

Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains

Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376

Functional Repression of cAMP Response Element in 6-Hydroxydopamine-treated Neuronal Cells

Chalovich, E. M., Zhu, J.-H., Caltagarone, J., Bowser, R., & Chu, C. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602632200 · Cited by 1,371

3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists

CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278

NMDA-dependent superoxide production and neurotoxicity

Lafon-Cazal, M., Pietri, S., Culcasi, M., & Bockaert, J. (1993) · Nature · doi:10.1038/364535a0 · Cited by 1,183

Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?

Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 961

Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine

Thoenen, H., & Tranzer, J. P. (1968) · Naunyn-Schmiedebergs Archiv f�r Pharmakologie und Experimentelle Pathologie · doi:10.1007/bf00536990 · Cited by 862

Interaction of bovine erythrocyte superoxide dismutase with hydrogen peroxide. Inactivation of the enzyme

Hodgson, E. K., & Fridovich, I. (1975) · Biochemistry · doi:10.1021/bi00695a010 · Cited by 782

Handbook of Experimental Pharmacology, vol 14.

Freedman, A. D. (1972) · Archives of Internal Medicine · doi:10.1001/archinte.1972.03650020118031 · Cited by 774

Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G., & Youdim, M. B. H. (1988) · Journal of Neural Transmission · doi:10.1007/bf01244786 · Cited by 752

A radical hypothesis for neurodegeneration

Olanow, C. W. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90070-3 · Cited by 722

Pathology of Parkinson’s disease: Changes other than the nigrostriatal pathway

Jellinger, K. A. (1991) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159935 · Cited by 684

EFFECTS OF 6‐HYDROXYDOPAMINE ON CATECHOLAMINE CONTAINING NEURONES IN THE RAT BRAIN

Uretsky, N. J., & Iversen, L. L. (1970) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1970.tb02210.x · Cited by 653

Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors

Baik, J.-H., Picetti, R., Saiardi, A., Thiriet, G., Dierich, A., Depaulis, A., Le Meur, M., & Borrelli, E. (1995) · Nature · doi:10.1038/377424a0 · Cited by 650

Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Jackson-Lewis, V., Jakowec, M., Burke, R. E., & Przedborski, S. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90015-2 · Cited by 609

Toward an understanding of the molecular mechanisms of physiological cell death.

Vaux, D. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.3.786 · Cited by 608

Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease

Sofic, E., Lange, K. W., Jellinger, K., & Riederer, P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90355-b · Cited by 590

Time course of nigrostriatal degeneration in parkinson's disease: A detailed study of influential factors in human brain amine analysis

Riederer, P., & Wuketich, S. (1976) · Journal of Neural Transmission · doi:10.1007/bf01249445 · Cited by 577

The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease

Paulus, W., & Jellinger, K. (1991) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199111000-00006 · Cited by 554

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

Turski, L., Bressler, K., Jürgen Rettig, K., Löschmann, P.-A., & Wachtel, H. (1991) · Nature · doi:10.1038/349414a0 · Cited by 546

Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds

Tipton, K. F., & Singer, T. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13610.x · Cited by 539

Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine

Wagner, G. C., Ricaurte, G. A., Seiden, L. S., Schuster, C. R., Miller, R. J., & Westley, J. (1980) · Brain Research · doi:10.1016/0006-8993(80)91265-2 · Cited by 523

Role for Excitatory Amino Acids in Methamphetamine-Induced Nigrostriatal Dopaminergic Toxicity

Sonsalla, P. K., Nicklas, W. J., & Heikkila, R. E. (1989) · Science · doi:10.1126/science.2563176 · Cited by 490

Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study

Ricaurte, G. A., Schuster, C. R., & Seiden, L. S. (1980) · Brain Research · doi:10.1016/0006-8993(80)90952-x · Cited by 490

Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons.

Breese, G. R., & Traylor, D. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/xd59-xs65 · Cited by 487

Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain

Ricaurte, G. A., Guillery, R. W., Seiden, L. S., Schuster, C. R., & Moore, R. Y. (1982) · Brain Research · doi:10.1016/0006-8993(82)90198-6 · Cited by 479

Molecular Neurobiology of the Mammalian Brain

McGeer, P. L., Eccles, J. C., & McGeer, E. G. (1987) · Springer eBooks · doi:10.1007/978-1-4615-7497-2 · Cited by 475

A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra

Saggu, H., Cooksey, J., Dexter, D., Wells, F. R., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb11759.x · Cited by 454

Lesions of Central Norepinephrine Terminals with 6-OH-Dopamine: Biochemistry and Fine Structure

Bloom, F. E., Algeri, S., Groppetti, A., Revuelta, A., & Costa, E. (1969) · Science · doi:10.1126/science.166.3910.1284 · Cited by 420

Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice

Schulz, J. B., Matthews, R. T., Muqit, M. M. K., Browne, S. E., & Beal, M. F. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020936.x · Cited by 417

Brain Peroxidase and Catalase in Parkinson Disease

Ambani, L. M., Van Woert, M. H., & Murphy, S. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490440064010 · Cited by 402

The neurochemistry of Parkinson's disease: effect of L-dopa therapy.

Lloyd, K. G., Davidson, L., & Hornykiewicz, O. (1975) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30363-0 · Cited by 396

Functional Role of the Nigro‐Neostriatal Dopamine Neurons*)

Andén, N., Dahlström, A., Fuxe, K., & Larsson, K. (1966) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1966.tb00389.x · Cited by 390

In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs implications for the origin of extracellular DOPAC

Zetterström, T., Sharp, T., Collin, A. K., & Ungerstedt, U. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90110-0 · Cited by 378

The catalepsy test: Its ups and downs.

Sanberg, P. R., Bunsey, M. D., Giòrdano, M., & Norman, A. B. (1988) · Behavioral Neuroscience · doi:10.1037//0735-7044.102.5.748 · Cited by 375

Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement

Cleeter, M. W. J., Cooper, J. M., & Schapira, A. H. V. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09789.x · Cited by 371

Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice

Otto, D., & Unsicker, K. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-06-01912.1990 · Cited by 366

Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease

Hartley, A., Stone, J. M., Heron, C., Cooper, J. M., & Schapira, A. H. V. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63051987.x · Cited by 361

Mechanisms of action of 6-hydroxydopamine

Sachs, C., & Jonsson, G. (1975) · Biochemical Pharmacology · doi:10.1016/0006-2952(75)90304-4 · Cited by 357

Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3, 4-methylenedioxymethamphetamine

Nash, J. F., & Yamamoto, B. K. (1992) · Brain Research · doi:10.1016/0006-8993(92)90713-j · Cited by 354

Apoptosis and necrosis. Basic types and mechanisms of cell death.

Buja, L. M., Eigenbrodt, M. L., & Eigenbrodt, E. H. (1993) · PubMed · Cited by 351

1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles

Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y., & Minakami, S. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90498-c · Cited by 319

Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys

Seiden, L. S., Fischman, M. W., & Schuster, C. R. (1976) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(76)90030-2 · Cited by 307

MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease

Gerlach, M., Riederer, P., Przuntek, H., & Youdim, M. B. H. (1991) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(91)90073-q · Cited by 307

Role of dopamine in the neurotoxic effects of methamphetamine.

Schmidt, C. J., Ritter, J. K., Sonsalla, P. K., Hanson, G. R., & Gibb, J. W. (1985) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22853-1 · Cited by 300

Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity

Heikkila, R. E., Nicklas, W. J., Vyas, I., & Duvoisin, R. C. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90580-4 · Cited by 300

The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons

Ben‐Shachar, D., Eshel, G., Finberg, J. P. M., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb11444.x · Cited by 299

Glutathione peroxidase activity in Parkinson's disease brain

Kish, S. J., Morito, C., & Hornykiewicz, O. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90078-3 · Cited by 299

Decreased dopamine in the retinas of patients with Parkinson's disease.

Harnois, C., & Paolo, T. D. (1990) · PubMed · Cited by 286

Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine

Glinka, Y. Y., & Youdim, M. B. H. (1995) · European Journal of Pharmacology: Environmental Toxicology and Pharmacology · doi:10.1016/0926-6917(95)90040-3 · Cited by 283

The role of environmental toxins in the etiology of Parkinson's disease

Tanner, C. M. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90135-5 · Cited by 276

Methamphetamine-induced neuronal damage: A possible role for free radicals

De Vito, M. J., & Wagner, G. C. (1989) · Neuropharmacology · doi:10.1016/0028-3908(89)90130-5 · Cited by 270

Rapid Communication: Attenuation of Methamphetamine‐Induced Neurotoxicity in Copper/Zinc Superoxide Dismutase Transgenic Mice

Cadet, J. L., Sheng, P., All, S., Rothman, R., Carlson, E., & Epstein, C. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62010380.x · Cited by 263

The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine‐depleted rats and MPTP‐treated monkeys

Klockgether, T., Turski, L., Honoré, T., Zhang, Z., Gash, D. M., Kurlan, R., & Greenamyre, J. T. (1991) · Annals of Neurology · doi:10.1002/ana.410300513 · Cited by 258

EFFECT OF 6-HYDROXYDOPAMINE AND SOME OTHER COMPOUNDS ON THE CONCENTRATION OF NOREPINEPHRINE IN THE HEARTS OF MICE

Porter, C. C., Totaro, J. A., & Stone, C. A. (1963) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)26555-7 · Cited by 233

Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey

Pifl, C., Schingnitz, G., & Hornykiewicz, O. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90080-8 · Cited by 224

Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine

Seiden, L. S., & Vosmer, G. (1984) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(84)90125-4 · Cited by 221

Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal

Schapira, A. H. V. (1994) · Movement Disorders · doi:10.1002/mds.870090202 · Cited by 219

Circling behavior in rats with partial, unilateral nigro-striatal lesions: Effect of amphetamine, apomorphine, and DOPA

Hefti, F., Melamed, E., Sahakian, B. J., & Wurtman, R. J. (1980) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(80)90353-6 · Cited by 218

Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels

Kogan, F. J., Nichols, W. K., & Gibb, J. W. (1976) · European Journal of Pharmacology · doi:10.1016/0014-2999(76)90090-x · Cited by 216

Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons

Dipasquale, B., Marini, A. M., & Youle, R. J. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)92101-o · Cited by 214

Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease

Mavridis, M., Degryse, A.-D., Lategan, A. J., Marien, M. R., & Colpaert, F. C. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90345-o · Cited by 211

Free Radical‐Generated Neurotoxicity of 6‐Hydroxydopamine

Kumar, R., Agarwal, A. K., & Seth, P. K. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041703.x · Cited by 202

EFFECTS OF L-DOPA AND L-TRYPTOPHAN ON THE CEREBRAL BLOOD FLOW IN THE DOG

Ekström-Jodal, B., Essen, C. V., Hauggendal, E., & Roos, B.-E. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1974.tb01342.x · Cited by 201

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost?

German, D. C., Dubach, M., Askari, S., Speciale, S. G., & Bowden, D. M. (1988) · Neuroscience · doi:10.1016/0306-4522(88)90320-x · Cited by 200

Animal Models of Parkinsonism Using Selective Neurotoxins: Clinical and Basic Implications

Zigmond, M. J., & Stricker, E. M. (1989) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)60277-9 · Cited by 199

Nigral and extranigral pathology in Parkinson's disease.

Braak, H., Braak, E., Yilmazer‐Hanke, D., Schultz, C., de Vos, R. A. I., & Jansen, E. N. H. (1995) · PubMed · Cited by 198

Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats

Ben‐Shachar, D., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb06432.x · Cited by 197

CNS stimulants: two distinct mechanisms of action for amphetamine-like drugs

McMillen, B. A. (1983) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(83)90477-7 · Cited by 195

Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice.

Sonsalla, P. K., Riordan, D. E., & Heikkila, R. E. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22956-1 · Cited by 184

Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity

O'Dell, S. J., Weihmuller, F. B., & Marshall, J. F. (1991) · Brain Research · doi:10.1016/0006-8993(91)91461-9 · Cited by 181

Morphine versus haloperidol catalepsy in the rat: A behavioral analysis of postural support mechanisms

De Ryck, M., Schallert, T., & Teitelbaum, P. (1980) · Brain Research · doi:10.1016/0006-8993(80)90781-7 · Cited by 181

Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment

Ricaurte, G. A., William Langston, J., Delanney, L. E., Irwin, I., Peroutka, S. J., & Forno, L. S. (1986) · Brain Research · doi:10.1016/0006-8993(86)90905-4 · Cited by 180

Parkinson's Disease: Activity of L-Dopa Decarboxylase in Discrete Brain Regions

Lloyd, K., & Hornykiewicz, O. (1970) · Science · doi:10.1126/science.170.3963.1212 · Cited by 176

Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat

COLPAERT, F. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90110-9 · Cited by 169

Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.

Chiueh, C. C., Markey, S. P., Burns, R. S., Johannessen, J. N., Jacobowitz, D. M., & Kopin, I. J. (1984) · PubMed · Cited by 169

1‐Methyl‐4‐Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism

Storey, E., Hyman, B. T., Jenkins, B., Brouillet, E., Miller, J. M., Rosen, B. R., & Beal, M. F. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10080.x · Cited by 164

Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence

Cadet, J. L., Katz, M., Jackson-Lewis, V., & Fahn, S. (1989) · Brain Research · doi:10.1016/0006-8993(89)91530-8 · Cited by 163

Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Moratalla, R., Quinn, B., DeLanney, L. E., Irwin, I., Langston, J. W., & Graybiel, A. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3859 · Cited by 158

Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis

Date, I., Felten, D. L., & Felten, S. Y. (1990) · Brain Research · doi:10.1016/0006-8993(90)90088-s · Cited by 158

Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus

Mitchell, I., Cross, A. J., Sambrook, M. A., & Crossman, A. R. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90424-0 · Cited by 157

Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study

Oestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1994) · Brain Research · doi:10.1016/0006-8993(94)90833-8 · Cited by 156

Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP

Seniuk, N. A., Tatton, W. G., & Greenwood, C. E. (1990) · Brain Research · doi:10.1016/0006-8993(90)91055-l · Cited by 153

Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity

Przedborski, S., Jackson-Lewis, V. R., Muthane, U. B., Jiang, H., Ferreira, M., Naini, A., & Fahn, S. (1993) · Annals of Neurology · doi:10.1002/ana.410340515 · Cited by 151

Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens

Abekawa, T., Ohmori, T., & Koyama, T. (1994) · Brain Research · doi:10.1016/0006-8993(94)90033-7 · Cited by 149

Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease

Sundström, E., Fredriksson, A., & Archer, T. (1990) · Brain Research · doi:10.1016/0006-8993(90)91656-2 · Cited by 145

Further studies on the generation of hydrogen peroxide by 6-hydroxydopamine. Potentiation by ascorbic acid.

Heikkila, R. E., & Cohen, G. (1972) · PubMed · Cited by 143

Rapid ATP Loss Caused by Methamphetamine in the Mouse Striatum: Relationship Between Energy Impairment and Dopaminergic Neurotoxicity

Chan, P., Monte, D. A. D., Luo, J. J., DeLanney, L. E., Irwin, I., & Langston, J. W. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62062484.x · Cited by 141

Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse

Heikkila, R. E., Sieber, B.-A., Manzino, L., et al. (1989) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159727 · Cited by 139

Increased Iron in the Substantia Nigra Compacta of the MPTP‐Lesioned Hemiparkinsonian African Green Monkey: Evidence from Proton Microprobe Elemental Microanalysis

Temlett, J. A., Landsberg, J. P., Watt, F., & Orime, G. W. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62010134.x · Cited by 137

Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat

Mochizuki, H., Nakamura, N., Nishi, K., & Mizuno, Y. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90271-2 · Cited by 136

Effects of Brain-derived Neurotrophic Factor on 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in Monkeys

Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O., & Hashimoto, N. (1995) · Neurosurgery · doi:10.1227/00006123-199510000-00018 · Cited by 134

Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease

Löschmann, P. A., Lange, K. W., Kunow, M., Rettig, K.-J., Jähnig, P., Honoré, T., Turski, L., Wachtel, H., Jenner, P. G., & MARSDEN, C. D. (1991) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02259538 · Cited by 134

Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies

Naoi, M., Maruyama, W., Dostert, P., et al. (1996) · Brain Research · doi:10.1016/0006-8993(95)01325-3 · Cited by 130

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro

Rossetti, Z. L., Soroiut, A., Sharp, D. E., Hadjiconstantinou, M., & Neff, N. H. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90674-0 · Cited by 129

Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity

Gibb, J. W., & Kogan, F. J. (1979) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00500283 · Cited by 129

Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons.

Breese, G. R., & Traylor, T. D. (1970) · PubMed · Cited by 127

Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions

Elsworth, J. D., Deutch, A. Y., Redmond, D. E., Taylor, J. R., Sladek, J. R., & Roth, R. H. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90212-1 · Cited by 125

6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation

Monteiro, H. P., & Winterbourn, C. C. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90512-1 · Cited by 125

Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease.

Jellinger, K. A., Linert, L., Kienzl, E., Herlinger, E., & Youdim, M. B. H. (1995) · PubMed · Cited by 121

In vivo monoamine oxidase inhibition by d-amphetamine

Miller, H. H., Shore, P. A., & Clarke, D. E. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90429-3 · Cited by 120 · cited 1×

Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain

Perumal, A. S., Gopal, V. B., Tordzro, W. K., Cooper, T. B., & Cadet, J. L. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90142-k · Cited by 120

MK‐801 Fails to Protect Against the Dopaminergic Neuropathology Produced by Systemic 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mice or Intranigral 1‐Methyl‐4‐Phenylpyridinium in Rats

Sonsalla, P. K., Zeevalk, G. D., Manzino, L., Giovanni, A., & Nicklas, W. J. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10081.x · Cited by 119

Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs

Wagner, G. C., Seiden, L. S., & Schuster, C. R. (1979) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(79)90076-0 · Cited by 119

β-Carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): Endogenous factors underlying idiopathic parkinsonism?

Collins, M. A., & Neafsey, E. J. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90016-3 · Cited by 114

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level

Kupsch, A. R., Sautter, J., Schwarz, J., Riederer, P. F., Gerlach, M., & Oertel, W. H. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00917-1 · Cited by 110

Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons

Hantraye, P., Varastet, M., Peschanski, M., RICHE, D., Césaro, P., Jc, W., & Mazière, M. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90295-q · Cited by 107

In vivo trapping of hydroxyl free radicals in the striatum utilizing intracranial microdialysis perfusion of salicylate: effects of MPTP, MPDP+, and MPP+

Obata, T., & Chiueh, C. C. (1992) · Journal of Neural Transmission · doi:10.1007/bf01245361 · Cited by 106

Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers

Sengstock, G. J., Olanow, C. W., Menzies, R. A., Dunn, A. J., & Arendash, G. W. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490350109 · Cited by 105

Developing a stable bilateral model of parkinsonism in rhesus monkeys

Smith, R. D., Zhang, Z., Kurlan, R., McDermott, M., & Gash, D. M. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90176-g · Cited by 104

Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity

Schulz, J. B., Ross Henshaw, D., Matthews, R. T., & Flint Beal, M. (1995) · Experimental Neurology · doi:10.1016/0014-4886(95)90033-0 · Cited by 103

Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset

Pérez‐Otaño, I., Herrero, M. T., Oset, C., CEBALLOS, M. L. D., Luquín, M. R., Obeso, J. A., & del Rı́o, J. A. (1991) · Brain Research · doi:10.1016/0006-8993(91)91444-6 · Cited by 98

Identification and quantification of 1,2,3,4-tetrahydro-β-carboline, 2-methyl-1,2,3,4-tetrahydro-β-carboline, and 6-methoxy-1,2,3,4-tetrahydro-β-carboline as in vivo constituents of rat brain and adrenal gland

Barker, S. A., Harrison, R. E. W., Monti, J. A., Brown, G. B., & Christian, S. T. (1981) · Biochemical Pharmacology · doi:10.1016/0006-2952(81)90278-1 · Cited by 96

The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment

Irwin, I., Finnegan, K. T., DeLanney, L. E., Monte, D. A. D., & Langston, J. W. (1992) · Brain Research · doi:10.1016/0006-8993(92)90473-m · Cited by 95

Neurology: Predicting Parkinson's disease

Snyder, S. H., & D’Amato, R. J. (1985) · Nature · doi:10.1038/317198a0 · Cited by 95

Dopamine-glutamate interactions in methamphetaminc-induced neurotoxicity

Marshall, J. F., O’Dell, S. J., & Weihmuller, F. B. (1993) · Journal of Neural Transmission · doi:10.1007/bf01245234 · Cited by 93

Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice

Marien, M. R., Briley, M., & Colpaert, F. C. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90489-5 · Cited by 92

Parkinson's disease : anatomy, pathology and therapy

Streifler, M. (1990) · Raven Press eBooks · Cited by 91

Behavioural pharmacology of glutamate in the basal ganglia

Schmidt, W., Bubser, M., & Hauber, W. (1992) · PubMed · doi:10.18419/opus-6924 · Cited by 91

Iron induces degeneration of nigrostriatal neurons

Sengstock, G. J., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90118-h · Cited by 90

Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes

During, M. J., Freese, A. B., Deutch, A. Y., Kibat, P. G., Sabel, B. A., Langer, R., & Roth, R. H. (1992) · Experimental Neurology · doi:10.1016/0014-4886(92)90053-s · Cited by 90

Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice

Kupsch, A. R., Gerlach, M., Pupeter, S. C., Sautter, J., Dirr, A., Arnold, G., Opitz, W., Przuntek, H., Riederer, P. F., & Oertel, W. H. (1995) · Neuroreport · doi:10.1097/00001756-199503000-00009 · Cited by 87

Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extra-striatal dopaminergic nuclei

Morgan, M. E., & Gibb, J. W. (1980) · Neuropharmacology · doi:10.1016/0028-3908(80)90010-6 · Cited by 86

Die Parkinson-Krankheit

Berg, D., & Riederer, P. F. (2004) · Springer eBooks · doi:10.1007/978-3-642-18741-4_8 · Cited by 83

Dopamine uptake inhibitory capacities of β-carboline and 3,4-dihydro-β-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products

Drucker, G. E., Raikoff, K., Neafsey, E. J., & Collins, M. A. (1990) · Brain Research · doi:10.1016/0006-8993(90)90318-6 · Cited by 83

The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates

Lange, K. W., L�schmann, P.-A., Sofic, E., Burg, M., HOROWSKI, R., Kalveram, K. T., Wachtel, H., & Riederer, P. F. (1993) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00167234 · Cited by 81

The MPTP-treated mouse as a model of Parkinsonism: How good is it?

Heikkila, R. E., & Sonsalla, P. K. (1992) · Neurochemistry International · doi:10.1016/0197-0186(92)90256-q · Cited by 77

Serotonergic sprouting in primate MTP-induced hemiparkinsonism

Gaspar, P., Febvret, A., & Colombo, J. A. (1993) · Experimental Brain Research · doi:10.1007/bf00230443 · Cited by 77

Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey

Crossman, A. R., Peggs, D., Boyce, S., Luquin, M. R., & Sambrook, M. A. (1989) · Neuropharmacology · doi:10.1016/0028-3908(89)90221-9 · Cited by 76

Are NMDA antagonistic properties relevant for antiparkinsonianlike activity in rats?—Case of amantadine and memantine

Danysz, W., Gossel, M., Zajaczkowski, W., et al. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02253435 · Cited by 76

The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease

Pifl, C., Schingnitz, G., & Hornykiewicz, O. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90066-3 · Cited by 74

The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+)

Carboni, S., Melis, F., Pani, L., Hadjiconstantinou, M., & Rossetti, Z. L. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90131-r · Cited by 72

Progressive Changes in Striatal Dopaminergic Markers, Nigral Volume, and Rotational Behavior Following Iron Infusion into the Rat Substantia Nigra

Sengstock, G. J., Olanow, C. W., Dunn, A. J., Barone, S., & Arendash, G. W. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1187 · Cited by 72

Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease?

Russ, H., Mihatsch, W., Gerlach, M., Riederer, P. F., & Przuntek, H. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90171-o · Cited by 71

Antiparkinsonian actions of glutamate antagonists — alone and with L-DOPA: A review of evidence and suggestions for possible mechanisms

Starr, M. S. (1995) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02251229 · Cited by 69

Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice

Kupsch, A. R., Löschmann, P. A., Sauer, H., Arnold, G., Renner, P., Pufal, D., Burg, M., Wachtel, H., ten Bruggencate, G., & Oertel, W. H. (1992) · Brain Research · doi:10.1016/0006-8993(92)91660-7 · Cited by 69

Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes

Mithöfer, K., Sandy, M. S., Smith, M. T., et al. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90498-l · Cited by 68

Responsibility of extrastriatal areas for the appearance of psychotic symptoms (Clinical and biochemical human post-mortem findings)

Birkmayer, W., & Riederer, P. F. (1975) · Journal of Neural Transmission · doi:10.1007/bf01663632 · Cited by 67

Marked locomotor stimulation in monoamine-depleted mice following treatment with atropine in combination with clonidine

Carlsson, M. L., & Carlsson, A. (1989) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02263486 · Cited by 66

Tyrosine Hydroxylase Activity in Caudate Nucleus from Parkinson's Disease: Effects of Iron and Phosphorylating Agents

Rausch, W., Hirata, Y., Nagatsu, T., Riederer, P. F., & Jellinger, K. A. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb13250.x · Cited by 65

Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets

Rose, S., Nomoto, M., Jackson, E. A., Gibb, W. R. G., Jaehnig, P., Jenner, P. G., & MARSDEN, C. D. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90800-w · Cited by 64

Biochemical and Immunocytochemical Changes Induced by Intrastriatal 6-Hydroxydopamine Injection in the Rat Nigrostriatal Dopamine Neuron System: Evidence for Cell Death in the Substantia Nigra

Ichitani, Y., Okamura, H., Nakahara, D., Nagatsu, I., & Ibata, Y. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1205 · Cited by 61

Pathology of Parkinson’s Syndrome

Jellinger, K. A. (1989) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-73899-9_2 · Cited by 59

Effects of MPTP, MPP+ and paraquat on mitochondrial potential and oxidative stress

Lambert, C. E., & Bondy, S. C. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90365-2 · Cited by 59

CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies.

Riederer, P. F., Rausch, W., Birkmayer, W., Jellinger, K. A., & Seemann, D. (1978) · PubMed · Cited by 57

Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids.

Gerlach, M., Riederer, P. F., & Youdim, M. B. H. (1996) · PubMed · Cited by 55

Strain differences in systematic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier

Riachi, N. J., & Harik, S. I. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90189-0 · Cited by 54

Toxic Effects of Iron for Cultured Mesencephalic Dopaminergic Neurons Derived from Rat Embryonic Brains

Michel, P. P., Vyas, S., & Agid, Y. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08882.x · Cited by 51

MRI, brain iron and experimental Parkinson's disease

Hall, S., Rutledge, J. N., & Schallert, T. J. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90247-i · Cited by 49

Parkinson's Disease: From Basic Research to Treatment

楢林, 博., 永津, 俊., 柳澤, 信., & 水野, 美. (1993) · Raven Press eBooks · Cited by 47

The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability.

Wr, G., Fearnley, J., & Aj, L. (1990) · PubMed · Cited by 43

The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons.

Bringmann, G., God, R., Feineis, D., Wesemann, W., Riederer, P. F., Rausch, W., Reichmann, H., & Sontag, K. ‐. (1995) · PubMed · Cited by 43

Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin

Ueki, A., Chong, P. N., Albanese, A., Rose, S., Chivers, J. K., Jenner, P. G., & MARSDEN, C. D. (1989) · Neuropharmacology · doi:10.1016/0028-3908(89)90122-6 · Cited by 42

Intranigral injected iron progressively reduces striatal dopamine metabolism

Wesemann, W., Blaschke, S., Solbach, M., Grote, C., Clement, H. ‐., & Riederer, P. F. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260941 · Cited by 39

Absence of 6‐Hydroxydopamine in the Rat Brain After Treatment with Stimulants and Other Dopaminergic Agents: A Mass Fragmentographic Study

Karoum, F., Chrapusta, S. J., Egan, M. F., & Wyatt, R. J. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13630.x · Cited by 38

Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3-6-tetrahydropyridine (MPTP)-treated rat

Desole, M. S., Esposito, G., Fresu, L. G., et al. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90274-o · Cited by 37

1-Methyl-4-phenylpyridine (MPP+): Regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation

Altar, C. A., Heikkila, R. E., Manzino, L., & Marien, M. R. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90573-x · Cited by 37

MPTP-induced parkinsonism

Stern, Y. (1990) · Progress in Neurobiology · doi:10.1016/0301-0082(90)90003-y · Cited by 36

Changes in lipid peroxidation induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in mouse brain homogenates

Ríos, C., & Tapia, R. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90521-0 · Cited by 35

1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline, a new inhibitor of complex I.

Janetzky, B., God, R., Bringmann, G., & Reichmann, H. (1995) · PubMed · Cited by 34

Effects of pargyline and pyrogallol on the methamphetamine-induced dopamine depletion

Kita, T., Wagner, G. C., Philbert, M. A., et al. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf03160110 · Cited by 32

Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine

Santiago, M., Granero, L. M., Machado, A., & Cano, J. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00202-v · Cited by 31

Striatal dopamine and homovanillic acid in Huntington's Disease

Reynolds, G. P., & Garrett, N. (1986) · Journal of Neural Transmission · doi:10.1007/bf01256491 · Cited by 29

Biochemical lesions of the nigrostriatal system by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) and derivatives.

Grote, C., Hw, C., Wesemann, W., Bringmann, G., Feineis, D., Riederer, P. F., & Sontag, K. ‐. (1995) · PubMed · Cited by 28

The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine

Gibb, W. R. G., Terruli, M., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Movement Disorders · doi:10.1002/mds.870040109 · Cited by 27

GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice

Fazzini, E., Durso, R., Davoudi, H., et al. (1990) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(90)90199-w · Cited by 25

Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium studied by microdialysis in freely moving rats

Espino, A., Cutillas, B., Tortosa, A., Ferrer, I., Bartrons, R., & Ambrosio, S. (1995) · Brain Research · doi:10.1016/0006-8993(95)00705-u · Cited by 24

Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin

Gerlach, M., Götz, M. E., Dirr, A., Kupsch, A. R., Janetzky, B., Oertel, W. H., Sautter, J., Schwarz, J., Reichmann, H., & Riederer, P. F. (1996) · Neurochemistry International · doi:10.1016/0197-0186(95)00063-e · Cited by 24

Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson disease, Alzheimer disease, and neurologically normal controls

Mizukawa, K., McGeer, E. G., & McGeer, P. L. (1993) · Molecular and Chemical Neuropathology · doi:10.1007/bf03160027 · Cited by 24

Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: Preliminary observations

Mihatsch, W., Russ, H., Gerlach, M., Riederer, P., & Przuntek, H. (1991) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02251138 · Cited by 24

Studies of the potentially endogenous toxin TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) in neuronal and glial cell cultures.

Rausch, W., Abdel‐mohsen, M., Koutsilieri, E., Ww, C., & Bringmann, G. (1995) · PubMed · Cited by 23

Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) after subchronic treatment in rats.

Sontag, K. ‐., Heim, C. C., Sontag, T. A., God, R., Reichmann, H., Wesemann, W., Rausch, W., Riederer, P., & Bringmann, G. (1995) · PubMed · Cited by 20

Methamphetamine and dopamine neurotoxicity: differential effects of agents interfering with glutamatergic transmission

Boireau, A., Bordier, F., Dubédat, P., & Doble, A. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11765-o · Cited by 18

The Pathophysiological Basis of Parkinson’s Disease

Gerlach, M., & Riederer, P. F. (1993) · Milestones in drug therapy · doi:10.1007/978-3-0348-6348-3_2 · Cited by 18

Parkinson's disease and the electron transport chain in postmortem brain.

Reichmann, H., Lestienne, P. P., Jellinger, K. A., & Riederer, P. F. (1993) · PubMed · Cited by 17

Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity.

Nwanze, E. A. C., Souverbie, F., Jonsson, G., et al. (1995) · PubMed · Cited by 17

Parkinson's Disease: From Basic Research to Treatment

Narabayashi, H., Yanagisawa, N., & Nagatsu, T. (1993) · Cited by 17

Effect of Clonidine and Atropine on Rest Tremor in the MPTP Monkey Model of Parkinsonism

Gomez‐Mancilla, B., Boucher, R., & Bédard, P. J. (1991) · Clinical Neuropharmacology · doi:10.1097/00002826-199108000-00008 · Cited by 16

Is complex II involved in the inhibition of mitochondrial respiration by N-methyl-4-phenylpyridinium cation (MMP+) and N-methyl-β-carbolines?

Krueger, M. J., Tan, A. K., Ackrell, B. A. C., & Singer, T. P. (1993) · Biochemical Journal · doi:10.1042/bj2910673 · Cited by 14

The effect of repeated administration of methamphetamine on dopamine uptake sites in rat striatum

Ikawa, K., Watanabe, A., Motohashi, N., & Kaneno, S. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)91022-7 · Cited by 14

Acute effects of 1-methyl-1,4-phenylpyridinium ion (MPP+) on purine metabolism in rat striatum studied in vivo using the microdialysis technique

Ballarín, M., Reiriz, J., Ambrosio, S., et al. (1989) · Brain Research · doi:10.1016/0006-8993(89)90052-8 · Cited by 14

Intranigral iron infusion in rats: A progressive model for excess nigral iron levels in Parkinson’s disease?

Arendash, G. W., Olanow, C. W., & Sengstock, G. J. (1993) · Key topics in brain research · doi:10.1007/978-3-7091-9322-8_8 · Cited by 12

Neurochemical lesioning in the rat brain with iontophoretic injection of the 1-methyl-4-phenylpyridinium ion (MPP+)

Horst, G. J. T., Knigge, M. F., & der Wal, A. V. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90895-e · Cited by 9

Pathobiochemistry of the extrapyramidal system: a “short note” review

Riederer, P. F., Sofic, E., Rausch, W., Hebenstreit, G. F., & Bruinvels, J. (1989) · Key topics in brain research · doi:10.1007/978-3-7091-8994-8_17 · Cited by 9

Iron and neurotoxin intoxication: comparative in vitro and in vivo studies

Wesemann, W., Blaschke, S., Clement, H. ‐., Grote, C., Weiner, N., Kolasiewicz, W., & Sontag, K. ‐. (1993) · Key topics in brain research · doi:10.1007/978-3-7091-9322-8_7 · Cited by 6

Dopamine-Derived Isoquinolines as Dopaminergic Neurotoxins and Oxidative Stress

Maruyama, W., Nakahara, D., Dostert, P., Takahashi, T., & Naoi, M. (1995) · Advances in behavioral biology · doi:10.1007/978-1-4757-9145-7_83 · Cited by 5

Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease

Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., & Verna, J.-M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,246

Multi-target-Directed Ligands To Combat Neurodegenerative Diseases

Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152

Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice

Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824

Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP

Schober, A. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0938-y · Cited by 803

Proteasomal function is impaired in substantia nigra in Parkinson’s disease

McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653